Navigation Links
NIH-funded trial launched to assess experimental TB drug
Date:12/11/2012

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis. The clinical trialsponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Healthis being led by researchers at the Tuberculosis Research Unit at Case Western Reserve University in Cleveland. The study to take place in Cape Town, South Africa, will enroll 75 men and women with TB ages 18 to 65, including individuals who are also infected with HIV but not yet taking antiretroviral treatment.

In 2011, 8.7 million people worldwide became infected with TB, and 1.4 million people died, according to the World Health Organization. Co-infection with TB causes one quarter of all deaths among those infected with HIV. South Africa has the highest TB infection rate in the world and accounts for 5 percent of the global TB burden. The country also has the highest TB/HIV co-infection rate, 73 percent.

"New, simplified treatments that cure TB infection more quickly are desperately needed," said NIAID Director Anthony S. Fauci, M.D. "It has been nearly 50 years since a new drug specifically developed for TB was licensed. This is a relatively small study, but we hope it yields insights into whether this investigational drug shows promise in people who are newly diagnosed with TB, as laboratory and earlier clinical safety trials indicate it might."

The clinical trial will assess the investigational TB drug developed by AstraZeneca, based in London. In laboratory testing, the drug proved active against a wide range of drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis (Mtb), the bacterium that causes TB disease. In two preliminary human studies in the United States, testing multiple doses, the oral drug was generally well-tolerated. Some study participants experienced gastrointestinal and blood-related adverse events at higher doses, but these effects were reversible and not serious.

To be eligible to participate in the new trial, patients must have newly diagnosed pulmonary TB as confirmed through a positive sample of mucus and saliva (sputum). HIV-infected patients who are not currently taking antiretrovirals and who have a CD4+ T-cell count of greater than 350 cells per cubic millimeter are eligible for the study. CD4+ T-cells are a key marker of immune system health.

Study volunteers will be randomly assigned to one of five study groups, each with 15 participants. In four groups, all participants will receive a 14-day regimen of the experimental drug, but at different dosages and frequencies: 500 milligrams (mg) once daily; 500 mg twice daily; 800 mg twice daily; and 1200 mg twice daily.

The study lasts only 14 days because of the potential risk of drug resistance emerging in TB patients receiving a single drug for a prolonged period of time.

Participants in the fifth study group will receive the standard TB treatment of 14 days of rifafoura four-drug combination pill containing isoniazid, rifampin, ethambutol and pyrazinamidedosed according to the study participants' body weight. After the 14-day study, all participants will receive standard TB drugs to treat their disease.

Researchers will examine daily sputum samples from the study participants to determine whether the investigational drug is reducing their TB bacteria counts, and if so, to what extent. Information about clinical trial NCT01516203 is available at http://www.clinicaltrials.gov. For more information about TB research, visit the NIAID Tuberculosis webpage.


'/>"/>

Contact: Sara Crocoll
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIH-funded study finds high HIV infection rates among gay and bisexual black men in the US
2. NIH-funded analysis estimates effective PrEP dosing
3. Brain Tumor Vaccine Shows Promise in Early Trial
4. URMC clinical trial tests new regimen for hypertension
5. Analysis Finds Clinical Trials Often Small, of Poor Quality
6. US spends far more for health care than 12 industrialized nations, but quality varies
7. New Weight-Loss Drug Shows Promise in Trial
8. Palpitations are predictive of future atrial fibrillation
9. Trial Set to See if Drug Can Prevent Alzheimers
10. Experts call for clinical trials to test non-skeletal benefits of vitamin D
11. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... , ... Elisa Guajardo Carothers is not your typical author. She went from working as a ... she writes about God, when she isn’t swimming as a performing mermaid. , Her book ... (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before Lucifer ...
(Date:2/27/2017)... , ... February 26, 2017 , ... Miro is the ... sound and video system brings songs, movies, TV shows and much more apps for ... clear, high-definition sound. An immersive view of 1280 x 720 provides crisp images with ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... New Jersey ... rates, among all types and genders. And the need for advanced services is growing. ... and its top-rated cancer care program, in collaboration with their non-profit partners in their ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017   Vitasome ® ... of nutritional supplements using its groundbreaking new liposome technology. ... percent of potency through digestion per Physician,s Desk ... solve the problem of nutritional waste and are scientifically ... during digestive processes Improve bioavailability with ...
(Date:2/27/2017)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced that ... Raymond James and Associates, 38 th Annual ... Orlando, FL. Cowen and Company ... March 7, 2017 in Boston, MA. ... in Miami, FL. Individuals ...
(Date:2/27/2017)... -- Leading Countries, Technologies and Companies ... at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% ... of 9.1% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business ...
Breaking Medicine Technology: